Fighting bacterial infections
For healthier tomorrow
With more than 1,000 medicines in development, antibacterial antibodies could save 25,000 lives every year in Europe.
Antibacterial resistance is increasing, and too few antibiotics are being produced to solve the problem. Without action, we will return to the pre-antibiotic era. As many as 300 million people could die prematurely from bacterial infections over the next 35 years unless new antibacterial treatments are developed. Existing antibiotics act against a broad spectrum of disease-causing organisms and beneficial bacteria. Antibacterial monoclonal antibodies (mAbs) offer a more targeted therapy. This means they can slow the development of antibiotic resistance and reduce the duration and toxicity of antibiotic treatment.
Antibacterial resistance is increasing, and too few antibiotics are being produced to solve the problem. Without action, we will return to the pre-antibiotic era. As many as 300 million people could die prematurely from bacterial infections over the next 35 years unless new antibacterial treatments are developed. Existing antibiotics act against a broad spectrum of disease-causing organisms and beneficial bacteria. Antibacterial monoclonal antibodies (mAbs) offer a more targeted therapy. This means they can slow the development of antibiotic resistance and reduce the duration and toxicity of antibiotic treatment.
With more than 1,000 medicines in development, antibacterial antibodies could save 25,000 lives every year in Europe.
Antibacterial resistance is increasing, and too few antibiotics are being produced to solve the problem. Without action, we will return to the pre-antibiotic era. As many as 300 million people could die prematurely from bacterial infections over the next 35 years unless new antibacterial treatments are developed. Existing antibiotics act against a broad spectrum of disease-causing organisms and beneficial bacteria. Antibacterial monoclonal antibodies (mAbs) offer a more targeted therapy. This means they can slow the development of antibiotic resistance and reduce the duration and toxicity of antibiotic treatment.
Fight against diabetes
For healthier tomorrow
With cell therapies, blood sugar levels could be controlled in nearly 4 million Europeans living with type 1 diabetes.
Cell therapy involves injecting or implanting living cells into a patient in order to treat the cause of their disease. The new cells take over the function of the defective cells, resolve the disease, and restore health. Basic examples of cell therapy include blood transfusion and bone marrow transplantation. Cell therapy for type 1 diabetes involves transplanting islet cells from a healthy donor pancreas into the patient, enabling their body to regain control of blood sugar levels.
Cell therapy involves injecting or implanting living cells into a patient in order to treat the cause of their disease. The new cells take over the function of the defective cells, resolve the disease, and restore health. Basic examples of cell therapy include blood transfusion and bone marrow transplantation. Cell therapy for type 1 diabetes involves transplanting islet cells from a healthy donor pancreas into the patient, enabling their body to regain control of blood sugar levels.
With cell therapies, blood sugar levels could be controlled in nearly 4 million Europeans living with type 1 diabetes.
Cell therapy involves injecting or implanting living cells into a patient in order to treat the cause of their disease. The new cells take over the function of the defective cells, resolve the disease, and restore health. Basic examples of cell therapy include blood transfusion and bone marrow transplantation. Cell therapy for type 1 diabetes involves transplanting islet cells from a healthy donor pancreas into the patient, enabling their body to regain control of blood sugar levels.
Creating a world without hemophilia B
For healthier tomorrow
Gene therapy can improve the quality of life of people living with disease by reducing the need for intensive, lifelong treatment.
Haemophilia B is a rare, severe blood disorder that affects patients from birth. A faulty gene means that the body cannot produce the protein Factor IX, which is needed for blood clotting. Genska terapija ima za cilj popraviti izravni uzrok genetske bolesti uvođenjem DNK u stanice radi kompenziranja abnormalnih ili neispravnih gena. Gene therapy aims to correct the direct cause of a genetic disease by introducing DNA into cells to compensate for abnormal or defective genes.
Haemophilia B is a rare, severe blood disorder that affects patients from birth. A faulty gene means that the body cannot produce the protein Factor IX, which is needed for blood clotting. Genska terapija ima za cilj popraviti izravni uzrok genetske bolesti uvođenjem DNK u stanice radi kompenziranja abnormalnih ili neispravnih gena. Gene therapy aims to correct the direct cause of a genetic disease by introducing DNA into cells to compensate for abnormal or defective genes.
Gene therapy can improve the quality of life of people living with disease by reducing the need for intensive, lifelong treatment.
Haemophilia B is a rare, severe blood disorder that affects patients from birth. A faulty gene means that the body cannot produce the protein Factor IX, which is needed for blood clotting. Genska terapija ima za cilj popraviti izravni uzrok genetske bolesti uvođenjem DNK u stanice radi kompenziranja abnormalnih ili neispravnih gena. Gene therapy aims to correct the direct cause of a genetic disease by introducing DNA into cells to compensate for abnormal or defective genes.
More pain‑free days for people with migraines
For healthier tomorrow
New therapies in development will reduce migraine attacks and enable patients to enjoy a better quality of life.
New treatments that use CGRP inhibitors offer fresh hope for patients with migraine, giving them the chance to regain control of their lives and improve their quality of life. CGRP inhibitors will provide a new opportunity for people with migraine by reducing the number and severity of migraine attacks
New treatments that use CGRP inhibitors offer fresh hope for patients with migraine, giving them the chance to regain control of their lives and improve their quality of life. CGRP inhibitors will provide a new opportunity for people with migraine by reducing the number and severity of migraine attacks
New therapies in development will reduce migraine attacks and enable patients to enjoy a better quality of life.
New treatments that use CGRP inhibitors offer fresh hope for patients with migraine, giving them the chance to regain control of their lives and improve their quality of life. CGRP inhibitors will provide a new opportunity for people with migraine by reducing the number and severity of migraine attacks
Fighting blood cancer
For healthier tomorrow
CAR‑T cell therapy could cure cancers that are currently incurable.
In CAR‑T cell therapy, scientists direct immune cells to target specific types of blood cancer, using the body’s own immune defense to fight cancer. A sample of the patient’s T‑cells is taken from their blood and genetically modified in the laboratory to add sensors (Chimeric Antigen Receptors) that look for specific cancers. The cells are allowed to multiply before being returned to the patient, where the new antigen receptors enable them to target and destroy cancer cells. The initial blood sample can be taken in any form.
In CAR‑T cell therapy, scientists direct immune cells to target specific types of blood cancer, using the body’s own immune defense to fight cancer. A sample of the patient’s T‑cells is taken from their blood and genetically modified in the laboratory to add sensors (Chimeric Antigen Receptors) that look for specific cancers. The cells are allowed to multiply before being returned to the patient, where the new antigen receptors enable them to target and destroy cancer cells. The initial blood sample can be taken in any form.
CAR‑T cell therapy could cure cancers that are currently incurable.
In CAR‑T cell therapy, scientists direct immune cells to target specific types of blood cancer, using the body’s own immune defense to fight cancer. A sample of the patient’s T‑cells is taken from their blood and genetically modified in the laboratory to add sensors (Chimeric Antigen Receptors) that look for specific cancers. The cells are allowed to multiply before being returned to the patient, where the new antigen receptors enable them to target and destroy cancer cells. The initial blood sample can be taken in any form.
Better prospects for patients with lung cancer
For healthier tomorrow
Combination therapy could prevent the deaths of 30,000 people with non-small cell lung cancer.
Combination therapy uses multiple drugs with different mechanisms of action to increase the chances that a patient’s cancer will be kept under control or even cured. Combinations can include immunotherapies, which enhance the patient’s immune response, and targeted therapies, which destroy cancer cells or prevent them from spreading. The combination of these therapies promises to achieve superior outcomes compared to individual drugs used in isolation.
Combination therapy uses multiple drugs with different mechanisms of action to increase the chances that a patient’s cancer will be kept under control or even cured. Combinations can include immunotherapies, which enhance the patient’s immune response, and targeted therapies, which destroy cancer cells or prevent them from spreading. The combination of these therapies promises to achieve superior outcomes compared to individual drugs used in isolation.
Combination therapy could prevent the deaths of 30,000 people with non-small cell lung cancer.
Combination therapy uses multiple drugs with different mechanisms of action to increase the chances that a patient’s cancer will be kept under control or even cured. Combinations can include immunotherapies, which enhance the patient’s immune response, and targeted therapies, which destroy cancer cells or prevent them from spreading. The combination of these therapies promises to achieve superior outcomes compared to individual drugs used in isolation.
Preventing infections
For healthier tomorrow
Microbiome therapies can prevent the recurrence of infections caused by Clostridium difficile. The number of cases could be reduced by 90%.
Clostridium difficile is a bacterium that can cause symptoms ranging from digestive problems to life-threatening inflammation of the colon. Microbiome therapies can prevent the recurrence of infections caused by the bacterium Clostridium difficile. The number of cases could be reduced by 90%.
Clostridium difficile is a bacterium that can cause symptoms ranging from digestive problems to life-threatening inflammation of the colon. Microbiome therapies can prevent the recurrence of infections caused by the bacterium Clostridium difficile. The number of cases could be reduced by 90%.
Microbiome therapies can prevent the recurrence of infections caused by Clostridium difficile. The number of cases could be reduced by 90%.
Clostridium difficile is a bacterium that can cause symptoms ranging from digestive problems to life-threatening inflammation of the colon. Microbiome therapies can prevent the recurrence of infections caused by the bacterium Clostridium difficile. The number of cases could be reduced by 90%.
Preventing liver transplantation
For healthier tomorrow
Therapies for NASH (non-alcoholic steatohepatitis) can reduce the buildup of fat in the liver. As a result, as many as 12,000 Europeans per year could avoid the need for a liver transplant.
Non-alcoholic steatohepatitis is a syndrome that develops in patients who are not alcoholics, and it causes liver damage that is histologically indistinguishable from alcoholic hepatitis. NASH involves inflammation and damage to liver cells, along with the accumulation of fat in the liver. Therapies for NASH (non-alcoholic steatohepatitis) can reduce the buildup of fat in the liver. As a result, as many as 12,000 Europeans per year could avoid the need for a liver transplant.
Non-alcoholic steatohepatitis is a syndrome that develops in patients who are not alcoholics, and it causes liver damage that is histologically indistinguishable from alcoholic hepatitis. NASH involves inflammation and damage to liver cells, along with the accumulation of fat in the liver. Therapies for NASH (non-alcoholic steatohepatitis) can reduce the buildup of fat in the liver. As a result, as many as 12,000 Europeans per year could avoid the need for a liver transplant.
Therapies for NASH (non-alcoholic steatohepatitis) can reduce the buildup of fat in the liver. As a result, as many as 12,000 Europeans per year could avoid the need for a liver transplant.
Non-alcoholic steatohepatitis is a syndrome that develops in patients who are not alcoholics, and it causes liver damage that is histologically indistinguishable from alcoholic hepatitis. NASH involves inflammation and damage to liver cells, along with the accumulation of fat in the liver. Therapies for NASH (non-alcoholic steatohepatitis) can reduce the buildup of fat in the liver. As a result, as many as 12,000 Europeans per year could avoid the need for a liver transplant.
Delaying Alzheimer’s disease
For healthier tomorrow
Scientists are researching more than 100 new drugs that could allow patients to live more independently.
Existing therapies address only the symptoms of Alzheimer’s disease, which is believed to be caused by the buildup of plaques in the brain. New therapies are currently being developed for early or mild forms of the disease, where symptoms are not yet apparent. These new treatments have the potential to delay the onset and/or progression of Alzheimer’s disease by reducing or even preventing the accumulation of plaques.
Existing therapies address only the symptoms of Alzheimer’s disease, which is believed to be caused by the buildup of plaques in the brain. New therapies are currently being developed for early or mild forms of the disease, where symptoms are not yet apparent. These new treatments have the potential to delay the onset and/or progression of Alzheimer’s disease by reducing or even preventing the accumulation of plaques.
Scientists are researching more than 100 new drugs that could allow patients to live more independently.
Existing therapies address only the symptoms of Alzheimer’s disease, which is believed to be caused by the buildup of plaques in the brain. New therapies are currently being developed for early or mild forms of the disease, where symptoms are not yet apparent. These new treatments have the potential to delay the onset and/or progression of Alzheimer’s disease by reducing or even preventing the accumulation of plaques.
